Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial

10.1016/s0140-6736(19)32135-x ◽

2019 ◽

Vol 394 (10208) ◽

pp. 1540-1550 ◽

Author(s):

Rajiv Agarwal ◽

Patrick Rossignol ◽

Alain Romero ◽

Dahlia Garza ◽

Martha R Mayo ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Resistant Hypertension ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736640403.793565817 ◽

2019 ◽

Author(s):

Carmine Zoccali ◽

Davide Bolignano

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Resistant Hypertension ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Patiromer plus spironolactone in resistant hypertension and CKD

Drug and Therapeutics Bulletin ◽

10.1136/dtb.2020.000033 ◽

2020 ◽

Vol 58 (8) ◽

pp. 119-119

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Resistant Hypertension ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo

AbstractReview of: Agarwal R, Rossignal P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019;394:1540–1550.

Download Full-text

Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial

Advances in Therapy ◽

10.1007/s12325-019-00943-4 ◽

2019 ◽

Vol 36 (6) ◽

pp. 1438-1454 ◽

Author(s):

Tadao Akizawa ◽

Manabu Iwasaki ◽

Tetsuro Otsuka ◽

Michael Reusch ◽

Toshihiro Misumi

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Controlled Trial ◽

Japanese Patients ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717954671.793466054 ◽

2012 ◽

Author(s):

John Eisman

Keyword(s):

Chronic Kidney Disease ◽

Parathyroid Hormone ◽

Kidney Disease ◽

Controlled Trial ◽

High Dose ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.735542506.793559665 ◽

2019 ◽

Author(s):

Carmine Zoccali ◽

Davide Bolignano

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Glycaemic Control ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Lowering Effect

Download Full-text

FP413EFFECT OF VITAMIN D SUPPLEMENTATION ON VASCULAR FUNCTION, ENDOTHELIAL AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfv177.12 ◽

2015 ◽

Vol 30 (suppl_3) ◽

pp. iii205-iii208

Author(s):

Ashok Kumar Yadav ◽

Vivek Kumar ◽

Vinod Kumar ◽

Manphool Singhal ◽

Anupam Lal ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Vitamin D ◽

Kidney Disease ◽

Vascular Function ◽

Controlled Trial ◽

Vitamin D Supplementation ◽

Inflammatory Biomarkers ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(13)70208-0 ◽

2014 ◽

Vol 2 (5) ◽

pp. 369-384 ◽

Author(s):

Anthony H Barnett ◽

Ambrish Mithal ◽

Jenny Manassie ◽

Russell Jones ◽

Henning Rattunde ◽

...

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): a pragmatic randomised, double-blind, placebo-controlled trial

BMC Medicine ◽

10.1186/s12916-020-01542-9 ◽

2020 ◽

Vol 18 (1) ◽

Author(s):

Keyword(s):

Chronic Kidney Disease ◽

Cost Effectiveness ◽

Kidney Disease ◽

Older Patients ◽

Controlled Trial ◽

Low Grade ◽

Double Blind ◽

Double Blind Placebo ◽

Bicarbonate Therapy ◽

Download Full-text

Effect of atorvastatin on kidney function in chronic kidney disease: A randomised double-blind placebo-controlled trial

Atherosclerosis ◽

10.1016/j.atherosclerosis.2010.07.053 ◽

2010 ◽

Vol 213 (1) ◽

pp. 218-224 ◽

Author(s):

Robert G. Fassett ◽

Iain K. Robertson ◽

Madeleine J. Ball ◽

Dominic P. Geraghty ◽

Jeff S. Coombes

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Kidney Function ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

1073-P: Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Soluble Guanylate Cyclase Stimulator Praliciguat in Patients with Diabetic Kidney Disease

Diabetes ◽

10.2337/db20-1073-p ◽

2020 ◽

Vol 69 (Supplement 1) ◽

pp. 1073-P

Author(s):

JOHN P. HANRAHAN ◽

IAN DE BOER ◽

GEORGE BAKRIS ◽

PHEBE WILSON ◽

JAMES D. WAKEFIELD ◽

...

Keyword(s):

Kidney Disease ◽

Guanylate Cyclase ◽

Diabetic Kidney Disease ◽

Soluble Guanylate Cyclase ◽

Controlled Trial ◽

Phase 2 ◽

Double Blind ◽

Diabetic Kidney ◽

Double Blind Placebo ◽

Soluble Guanylate Cyclase Stimulator

Download Full-text